Your browser doesn't support javascript.
loading
Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis.
Lackey, Leila G; Ng, Xinyi; Veldwijk, Jorien; Thokala, Praveen; Levitan, Bennett; Payne, Katherine; Ho, Martin; Tervonen, Tommi.
  • Lackey LG; Decision Support and Analysis Staff, Office of Program and Strategic Analysis, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Electronic address: leila.lackey@fda.hhs.gov.
  • Ng X; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
  • Veldwijk J; Erasmus School of Health Policy and Management & Erasmus Choice Modelling Center, Rotterdam, The Netherlands.
  • Thokala P; School of Health and Related Research, University of Sheffield, Sheffield, England, UK.
  • Levitan B; Global R&D Epidemiology, Janssen R&D, Titusville, NJ, USA.
  • Payne K; Manchester Centre for Health Economics, School of Health Sciences, The University of Manchester, Manchester, England, UK.
  • Ho M; Google, San Francisco, CA, USA.
  • Tervonen T; Kielo Research, Zug, Switzerland.
Value Health ; 26(4): 519-527, 2023 04.
Article en En | MEDLINE | ID: mdl-36764517
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article